Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | A166 |
| Synonyms | |
| Therapy Description |
A166 is an antibody-drug conjugate (ADC) that targets Erbb2 (Her2)-expressing tumor cells, which may have potential antitumor activity (PMID: 30841523). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| A166 | ADC A166|anti-HER2 ADC A166|A-166 | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 | A166 is an antibody-drug conjugate (ADC) that targets Erbb2 (Her2)-expressing tumor cells, which may have potential antitumor activity (PMID: 30841523). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03602079 | Phase Ib/II | A166 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | Completed | USA | 0 |